Geneos Wealth Management Inc. Boosts Stock Holdings in GSK PLC Sponsored ADR $GSK

Geneos Wealth Management Inc. lifted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 29.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,536 shares of the pharmaceutical company’s stock after acquiring an additional 1,244 shares during the quarter. Geneos Wealth Management Inc.’s holdings in GSK were worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Kingsview Wealth Management LLC increased its position in shares of GSK by 1.8% during the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company’s stock worth $590,000 after acquiring an additional 271 shares during the period. Rehmann Capital Advisory Group increased its holdings in GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company’s stock valued at $248,000 after buying an additional 279 shares during the last quarter. First PREMIER Bank increased its holdings in GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company’s stock valued at $181,000 after buying an additional 286 shares during the last quarter. Northwest Bank & Trust Co increased its holdings in GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock valued at $765,000 after buying an additional 289 shares during the last quarter. Finally, OneAscent Financial Services LLC increased its holdings in GSK by 3.9% in the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company’s stock valued at $297,000 after buying an additional 292 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on GSK. Berenberg Bank reissued a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, GSK has an average rating of “Reduce” and an average price target of $37.38.

GSK Stock Performance

NYSE GSK opened at $40.04 on Wednesday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $43.14. The company has a market capitalization of $81.55 billion, a PE ratio of 18.54, a P/E/G ratio of 2.01 and a beta of 0.53. The company has a fifty day moving average of $38.81 and a two-hundred day moving average of $38.50.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the prior year, the firm posted $0.43 earnings per share. GSK’s revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK’s dividend payout ratio is 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.